|
|
|
Neurogen Files with SEC
|
Business New Haven
9/3/2002
By: BNH
|
BRANFORD - Drug company Neurogen Corp. (NASDAQ: NRGN) has filed an application with the U.S. Securities & Exchange Commission to periodically sell up to $75 million in debt securities, common and preferred stock and warrants.
The company plans to use the net proceeds for research and development and general corporate purposes. The money may also go toward acquisitions of or investments in businesses, products and technologies, according to the shelf registration filing. Under such a filing, a company may sell securities from time to time in one or more separate offerings in amounts, at prices and on terms to be determined at the time of sale.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
